Comparison of the Antiviral Activity of Bictegravir against HIV-1 and HIV-2 Isolates and Integrase Inhibitor-Resistant HIV-2 Mutants.

Antimicrobial Agents and Chemotherapy
Robert A SmithUniversity of Washington-Dakar HIV-2 Study Group

Abstract

We compared the activity of the integrase inhibitor bictegravir against HIV-1 and HIV-2 using a culture-based, single-cycle assay. Values of 50% effective concentrations ranged from 1.2 to 2.5 nM for 9 HIV-1 isolates and 1.4 to 5.6 nM for 15 HIV-2 isolates. HIV-2 integrase mutants G140S/Q148R and G140S/Q148H were 34- and 110-fold resistant to bictegravir, respectively; other resistance-associated mutations conferred ≤5-fold changes in bictegravir susceptibility. Our findings indicate that bictegravir-based antiretroviral therapy should be evaluated in HIV-2-infected individuals.

References

Mar 12, 2004·The Journal of Biological Chemistry·Robert A SmithBradley D Preston
Jan 27, 2007·AIDS·Euridice Martinez-SteeleMaarten F Schim van der Loeff
Aug 23, 2008·The Journal of Antimicrobial Chemotherapy·B RoquebertUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Oct 31, 2008·Trends in Microbiology·Thushan I de SilvaSarah L Rowland-Jones
May 28, 2009·Antimicrobial Agents and Chemotherapy·Michel L NtemgwaMark A Wainberg
Jul 25, 2009·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·María SalgadoBerta Rodés
May 21, 2010·Retrovirology·Maarten F Schim van der LoeffHilton Whittle
Sep 10, 2010·AIDS·Charlotte CharpentierUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Dec 30, 2010·Antimicrobial Agents and Chemotherapy·Charlotte CharpentierUNKNOWN French ANRS HIV-2 Cohort (ANRS CO 05 VIH-2)
Mar 2, 2011·AIDS·Rodolphe ThiébautUNKNOWN immunology group of the ANRS CO5 HIV-2 cohort
Oct 6, 2011·AIDS·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Aug 16, 2012·Antiviral Therapy·Kevin PetersonRobert Colebunders
Apr 11, 2013·Antimicrobial Agents and Chemotherapy·Dana N RaugiUNKNOWN University of Washington-Dakar HIV-2 Study Group
Dec 19, 2013·Antiviral Research·Luis Menéndez-Arias, Mar Alvarez
Apr 22, 2014·Journal of Visualized Experiments : JoVE·Steven J Smith, Stephen H Hughes
Feb 19, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Diane DescampsSophie Matheron
Mar 3, 2015·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·Ana TreviñoVincent Soriano
Mar 27, 2015·Retrovirology·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Sep 24, 2015·Antimicrobial Agents and Chemotherapy·Robert A SmithUNKNOWN University of Washington-Dakar HIV-2 Study Group
Aug 18, 2016·Infection, Genetics and Evolution : Journal of Molecular Epidemiology and Evolutionary Genetics in Infectious Diseases·Benoit VisseauxCharlotte Charpentier
Mar 31, 2017·AIDS·Carmen de MendozaUNKNOWN Spanish HIV-2 Network
Apr 1, 2017·Journal of the International AIDS Society·Antoine JaquetFrançois Dabis
Apr 4, 2017·The Journal of Antimicrobial Chemotherapy·Silvia RequenaUNKNOWN Spanish HIV-2 Study Group
Jun 1, 2017·Antimicrobial Agents and Chemotherapy·Vincent H WuUNKNOWN University of Washington–Dakar HIV-2 Study Group
Sep 20, 2017·Antimicrobial Agents and Chemotherapy·Said A HassounahMark A Wainberg
Mar 29, 2018·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Sophie MatheronUNKNOWN France REcherche Nord&Sud Sida-Hiv Hépatites (ANRS) 159 HIV-2 Trial Study Group

❮ Previous
Next ❯

Citations

Apr 1, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Dirk BerzowRicardo Camacho
Apr 1, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elizabeth R Jenny-Avital
Aug 28, 2020·The New England Journal of Medicine·Geoffrey S GottliebRajesh T Gandhi
Feb 3, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Elizabeth R Jenny-Avital
Mar 3, 2021·Antimicrobial Agents and Chemotherapy·Kirsten L WhiteAnita Niedziela-Majka

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Related Papers

Antimicrobial Agents and Chemotherapy
Robert A SmithUniversity of Washington-Dakar HIV-2 Study Group
Retrovirology
Robert A SmithUniversity of Washington-Dakar HIV-2 Study Group
© 2022 Meta ULC. All rights reserved